What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
关于奥洛兹美医疗的13位分析师评级报告
A comprehensive examination of...Halozyme Therapeutics (NASDAQ:HALO) has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
在过去三个月中，13位分析师对Halozyme Therapeutics（纳斯达克股票代码：HALO）进行了分析，揭示了从看涨到看跌的不同观点。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
下表总结了他们最近的评估，说明了过去30天不断变化的情绪，并将其与前几个月进行了比较。
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $57.69, a high estimate of $71.00, and a low estimate of $50.00. This upward trend is evident, with the current average reflecting a 3.52% increase from the previous average price target of $55.73.
分析师评估的12个月目标股价揭示了进一步的见解，平均目标价为57.69美元，最高估计为71.00美元，低估值为50.00美元。这种上升趋势显而易见，当前的平均价格较之前的55.73美元的平均目标股价上涨了3.52％。
Breaking Down Analyst Ratings: A Detailed Examination
分解分析师评级：详细审查
A comprehensive examination of...
对金融专...
登录免费看全文
登录/注册